Mottet, N.

patient cancer prostate cancer prostate trial androgen therapy androgen deprivation therapy deprivation treatment disease study survival androgen deprivation result randomized lhrh-a bicalutamide hormone mortality radiation oncol metastatic phase castration urology orchiectomy fl utamide fracture evidence radiation therapy benefit european 10 yr group difference agonist score gleason prostate-speci fic antigen bicalutamide 150 mg monotherapy prostatectomy failure follow-up radiotherapy metastase table eortc suppression 11–25 metastatic prostate cancer surgery androgen suppression fi ndings metastatic disease placebo combination analysis diabetes utamide effect adjuvant acetate cancer-speci fic survival luteinizing 66 yr androgen blockade stage level ratio nonmetastatic control population morbidity antiandrogen leuprolide approach progression death